Characteristics Overall Incidence Non-incidence p-value
Patients, n (%) 176 (100) 58 (33.0) 118 (77.0)
Frequency of dose, n (%) 2320 (100) 80 (3.4) 2240 (96.6)
Course, median (IQR) 8 (4–14) 1 (1–4) 9 (4–14) <0.001*
Age, year, median (IQR) 56 (47–67) 55 (47–66) 56 (47–68) 0.762
BW, kg, median (IQR) 54 (50–60) 56 (50–61) 54 (49–60) 0.126
BMI, kg/m2, median (IQR) 21.8 (19.6–24.8) 22.2 (19.9–24.9) 21.8 (19.6–24.8) 0.407
Stage, n (%) 0.021*
I 481 (20.7) 9 (1.9) 472 (98.1)
II 1235 (53.2) 45 (3.6) 1190 (96.4)
III 283 (12.2) 9 (3.2) 274 (96.8)
IV 321 (13.8) 17 (5.3) 304 (94.7)
Stage, n (%) 0.195
I or II 1716 (74.0) 54 (3.1) 1662 (96.9)
III or IV 604 (26.0) 26 (4.3) 578 (95.7)
Metastasis, n (%) 321 (13.8) 17 (5.3) 304 (94.7) 0.067
Status, n (%) <0.001*
Preoperative 269 (11.6) 25 (9.3) 244 (90.7)
Postoperative 1729 (74.5) 38 (2.2) 1691 (97.8)
Recurrent progression 322 (13.9) 17 (5.3) 305 (94.7)
Dose, mg/body, median (IQR) 328 (300–378) 425 (382–482) 327 (300–368) <0.001*
Dose, n (%) <0.001*
2 mg/kg 22 (0.9) 0 (0) 22 (100)
4 mg/kg 2 (0.1) 0 (0) 2 (100)
6 mg/kg 2025 (87.3) 11 (0.5) 2014 (99.5)
8 mg/kg 271 (11.7) 69 (25.5) 202 (74.5)
Dexamethasone iv, n (%) 0.258
0 mg 2039 (87.9) 73 (3.6) 1966 (96.4)
6.6 mg 250 (10.8) 7 (2.8) 243 (97.2)
8.25 mg 31 (1.3) 0 (0) 31 (100)
Dexamethasone iv, n (%) 281 (12.1) 7 (2.5) 274 (97.5) 0.484
Glucocorticoids po, n (%) 22 (0.9) 0 (0) 22 (100) 1.000
NSAIDs, n (%) 84 (3.6) 6 (7.1) 78 (92.9) 0.067
Acetaminophen, n (%) 11 (0.5) 2 (18.2) 9 (81.8) 0.053
H1AT, n (%) 148 (6.4) 2 (1.4) 146 (98.6) 0.238